RxDoctor Payments Data

Allison Rutelonis

Nurse Practitioner · Tyler, TXNPI 1407340128

Payments from drug & device makers

$2,802in general payments, 2019–2025

Across 116 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$611
  • Takeda Pharmaceuticals U.S.A., Inc.$299
  • Teva Pharmaceuticals USA, Inc.$273
  • Novo Nordisk$189
  • Kaleo, Inc.$187
  • Grifols USA, LLC$168
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,72797%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,802 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$32,148
Medicare patients
105
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$21,762
EliquisApixaban12$4,654
Azelastine Hcl33$1,225
Albuterol Sulfate HfaAlbuterol Sulfate25$594
Levothyroxine Sodium78$566
Gabapentin46$492
Pantoprazole Sodium36$412
Potassium Chloride21$349
Tramadol Hcl19$329
Duloxetine Hcl12$292
Omeprazole29$282
Venlafaxine Hcl ErVenlafaxine Hcl13$253
Atorvastatin Calcium43$231
Ondansetron Hcl12$218
Losartan Potassium29$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$82$21,76221 claims
PfizerEliquis$93$4,65412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →